Mindrank Therapeutics (Suzhou) New Drug Research & Development Co. Ltd. has divulged molecular glue degraders comprising cereblon (CRBN) ligands acting as dual eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) and casein kinase 1 isoform α (CSNK1A1) degradation inducers. They are reported to be potentially useful for the treatment of cancer, Alzheimer’s disease, inflammatory disorders, autoimmune diseases and metabolic diseases.
Hutchmed Ltd. has identified antibody-drug conjugates comprising an antibody or antigen binding fragment covalently linked to a GTPase RAS or KRAS inhibitor through a linker reported to be useful for the treatment of cancer.
Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has synthesized GTPase KRAS wild-type and/or its mutant inhibitors reported to be useful for the treatment of cancer.
In non-small-cell lung cancer (NSCLC) and various other cancers, mutations in nuclear factor erythroid 2-related factor 2 (NRF2) cause aberrant activation of NRF2 transcriptional activity, resulting in therapeutic resistance and poor survival.
The limited efficacy of cancer immunotherapy is usually attributed to suboptimal antitumor T-cell generation, as well as impaired immunological memory development. MDX-2004 is a trispecific antibody-fusion protein developed by Modex Therapeutics Inc. that targets CD3, CD28 and CD137 on human T cells, which was designed to overcome these limitations by rejuvenating the immune system and enhancing antitumor immunity.
At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, researchers from Circle Pharma Inc. presented their recent work on developing novel compounds that specifically target cyclin D1 while avoiding the toxicity associated with targeting cyclin D3.
Researchers from Chantibody Therapeutics Inc. presented the preclinical characterization of CT-111, a trispecific antibody engineered to simultaneously target PD-1, CTLA-4, and VEGF.
Anticancer drugs that work simultaneously through multiple mechanisms are sought after because of their potential for greater efficacy and robustness to resistance. Researchers at Capital Medical University and Chinese Institutes for Medical Research generated 21 ternary hybrids containing phenylsulfonylfuroxan, b-carboline und hydroxamic acid moieties.
Arginase 1 (Arg1) is a key mediator of immune suppression, and its overexpression has been reported in multiple cancers, including renal cell carcinoma, pancreatic cancer, and head and neck cancer. However, clinical strategies aimed at inhibiting Arg1 function have achieved only limited success.
Radiopharm Theranostics Ltd. has been granted Bellberry Human Research Ethics Committee (HREC) approval in Australia to initiate a first-in-human phase I trial of its KLK3-targeting radiotherapeutic, RAD-402, for the treatment of metastatic or locally advanced prostate cancer.
RSS
